Focus on obesity drug treatments
The management of obesity is changing dramatically with the emergence of new drug treatments. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for this indication in Switzerland, and approval is currently being sought for a GLP-1 and glucose-dependent insulinotropic polypetide (GIP) co-agonist. Reimbursement conditions are restrictive, and patients are given only one opportunity to achieve the weight loss required for continued reimbursement. The popularity of these treatments has led to worldwide stock-outs for several months now, and it is essential that prescribers respect the indications so as not to prejudice obese patients. This article provides a review of the treatments available and the conditions under which they are reimbursed, as well as those that should be reimbursed soon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 20(2024), 866 vom: 20. März, Seite 570-574 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Focus sur les traitements médicamenteux de l’obésité |
|---|
| Beteiligte Personen: |
Favre, Lucie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
59392-49-3 |
|---|
| Anmerkungen: |
Date Completed 21.03.2024 Date Revised 21.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.53738/REVMED.2024.20.866.570 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369960556 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369960556 | ||
| 003 | DE-627 | ||
| 005 | 20240322001129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.53738/REVMED.2024.20.866.570 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369960556 | ||
| 035 | |a (NLM)38506456 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Favre, Lucie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Focus on obesity drug treatments |
| 246 | 3 | 3 | |a Focus sur les traitements médicamenteux de l’obésité |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2024 | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The management of obesity is changing dramatically with the emergence of new drug treatments. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for this indication in Switzerland, and approval is currently being sought for a GLP-1 and glucose-dependent insulinotropic polypetide (GIP) co-agonist. Reimbursement conditions are restrictive, and patients are given only one opportunity to achieve the weight loss required for continued reimbursement. The popularity of these treatments has led to worldwide stock-outs for several months now, and it is essential that prescribers respect the indications so as not to prejudice obese patients. This article provides a review of the treatments available and the conditions under which they are reimbursed, as well as those that should be reimbursed soon | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Gastric Inhibitory Polypeptide |2 NLM | |
| 650 | 7 | |a 59392-49-3 |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 20(2024), 866 vom: 20. März, Seite 570-574 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:866 |g day:20 |g month:03 |g pages:570-574 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.53738/REVMED.2024.20.866.570 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 866 |b 20 |c 03 |h 570-574 | ||